Imperative Care, a medical technology company focused on thromboembolic disease treatments, has appointed Jay Martin as Chief Commercial Officer. Martin will lead commercial strategy, expand strategic partnerships and build infrastructure to support the company's growth and commercialisation efforts. Martin brings over 25 years of executive leadership experience in medical devices, robotics and imaging. Most recently, he served as President of VulcanForms, where he helped build a backlog exceeding $1 billion in 18 months. He previously spent eight years at Globus Medical, serving as President of Imaging, Navigation and Robotics, and was part of the leadership team that grew the company from approximately $400 million to over $2 billion in revenue. The Campbell, California-based company develops treatments for patients suffering from blood clot formation in veins and arteries.

Imperative Care, a medical technology company treating thromboembolic disease, has closed an oversubscribed $100 million convertible note financing. The round was co-led by new investors Elevage Medical Technologies and Perceptive Advisors, alongside existing investor Catalio Capital Management. New investors Longaeva Partners and Brown Advisory participated, with support from existing backers including Ally Bridge Group and Bain Capital Life Sciences. Evan Melrose, CEO of Elevage Medical Technologies, has joined Imperative Care's board of directors. The funding will support commercialisation of the company's stroke and vascular thrombectomy portfolios, next-generation product development including the Telos robotic platform, and clinical evidence generation. Imperative Care's products have been used in over 78,000 procedures commercially. BofA Securities and J.P. Morgan served as joint placement agents.

Imperative Care introduces ischaemic stroke treatment catheter. The Zoom 4S catheter is designed to simplify stroke thrombectomy by reducing device exchanges. Imperative Care has launched the Zoom 4S catheter, an advanced thrombectomy device for treating ischaemic stroke. Marking the latest addition to its Zoom Stroke System, the new catheter aims to expand access to the ADAPT 2.0 technique. It aims to address a broader range of patient anatomies during aspiration thrombectomy procedures. It is designed to simplify stroke thrombectomy by reducing device exchanges and introducing a single setup approach. The ADAPT 2.0 technique, central to this advancement, involves positioning an intracranial 0.088in catheter closer to the clot and utilising an asymmetric tip design for targeted aspiration. The system applies Continuous Dual AspiraTion (CDAT) through two catheters for enhanced clot ingestion. First published in 2014, the original ADAPT technique showed the clinical benefits of direct aspiration as a frontline treatment for acute ischaemic stroke. US tariffs are shifting - will you react or anticipate? Don't let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. Expanding on this groundwork, Imperative Care has advanced the method with ADAPT 2.0, emphasising rapid thrombectomy procedures that do not require several device exchanges. Imperative Care chief technology officer Richard Leparmentier said: "At Imperative Care, Medicaldevice Network believe that it is its responsibility to bring the most advanced technologies to market, with the goal of improving patient outcomes by shaping the arc of innovation in stroke care. "With a focus on reducing treatment times and streamlining stroke procedures, Medicaldevice Network has purposefully engineered one simple Zoom setup to bring the key procedural benefits of the ADAPT 2.0 technique to more patients. "With the introduction of Zoom 4S, Imperative Care is heralding this new chapter of stroke care, as we believe this combination of technologies will provide physicians with the confidence to effectively address a broad range of clot locations using a single setup." The complete Zoom Stroke System includes catheters such as Zoom 35, 4S, 45, 55, 71 and 7X; as well as the Zoom 88 Large Distal Platform and Zoom 88 Support. In September 2025, Imperative Care received 510(k) clearance from the US Food and Drug Administration (FDA) for its Symphony thrombectomy system, which is designed to treat pulmonary embolism (PE).